HCS Pharma announces the closure of the “MIMLIVERonChip” project, funded by the French National Research Agency (ANR, project ANR 19 CE19-0020) and coordinated by BMBI Biomechanics and Bioengineering joint research unit (UTC/ CNRS), headed by Dr Cécile Legallais, CNRS research director. This project led to the publication of Taha Messelmani’s Read more…
This is the end of Rania‘s 6-month internship in HCS Pharma about a new liver biochip system. After a first publication “Development of Liver-on-Chip Integrating a Hydroscaffold Mimicking the Liver’s Extracellular Matrix” in collaboration with the University of Technology of Compiègne (UTC) using the BIOMIMESYS® Liver hydroscaffold™ and HepG2/C3A (hepatocellular Read more…
In Asia for a business trip, Nathalie Maubon, PhD, CEO & CSO of HCS Pharma, participated in a symposium during BioAsia event on late July, together with LumiSTAR Biotechnology (Taïwan) and Molecular Devices (USA). On this occasion, the 3 companies have highlighted their work on hiPSCs (human induced Pluripotent Stem Read more…
Rehovot (Israel) London (UK) and Lille (France) Vidac Pharma is a clinical stage biopharmaceutical company dedicated to discovering and developing First-in-class medicines to help people suffering from a range of oncologic and dermatologic diseases. Vidac Pharma and HCS Pharma announce cooperative agreement on acceleration of pre-clinical assays for Vidac Pharma Read more…
We are happy to share that Nathalie Maubon, PhD, our CEO/CSO is currently attending BioAsia Taiwan, organized in Taipei. The event aims at building on the success of recent years’ gatherings to bring together biotechnology and pharmaceutical executives and investors from North America, Europe and Asia, and explore business opportunities Read more…
We are really pleased to announce that we will be present in BioAsia-Taiwan and present our breakthrough technology BIOMIMESYS alongside our partners Molecular Devices (USA) and LumiSTAR Biotechnology (TW). We are 3 companies in 3 different continents unifying their strenghs to develop the best strategy to find new and more Read more…
After Japan, the business trip has been been continued in Taïwan for several days! As a scientist, I was really happy to see such open-mind spirit when I present BIOMIMESYS technology and how this kind of technology will change the drug discovery process and help the cell therapy/regenerative medicine in Read more…
Last week, we had the pleasure to participate in the conference about Alternatives to Animal Experimentation which was held last week in Biocitech park, Romainville, France. It was organized by Adebiotech think tank, and gathered researchers from private companies and academia, and also people from organizations like FC3R and PETA Read more…
Currently in Japan, it’s already been a week in Asia. Time goes by very quickly with 3 days of events, many appointments, visits from potential partners, a visit to the Kobe biopark and JETRO, and work appointments with our privileged partner, AS ONE.The 3 days in IDDST 2023 events in Read more…
Nathalie, founder, CEO and CSO of HCS Pharma will be present in BIO international convention that takes place in Boston, USA from the 5th to the 8th of June. Is it the place to be for a start-up like HCS Pharma, proposing a breakthrough technology that will revolutionnize the biotechnology Read more…
The Building Biology in 3D symposium of the Society for Laboratory Automation and Screening (SLAS) took place in Cambridge, United Kingdom, on March 20th and 21th 2023. This congress was the opportunity to discover the dynamic scientific environment of Cambridge. Because this event was focusing on 3D cell culture, most Read more…
Follow the webinar « From 2D to 3D » with miss Oceane Guyot, R&D dermarto cosmetology Project leader on ; – Tuesday, April 25, 2023 – 9AM (CEST) / 3PM (CST) / 4PM (JST) / 3AM (EST) – Thursday, April 27, 2023 – 5PM (CEST) / 11PM (CST) / 12PM (JST) / 11AM Read more…
We will be pleased to meet you in Paris from the 28th to 30th of March. Join Thierry DE CATHEU Business Director, Mathieu LAOUENAN Chief Commercial Officer, Paul COUVREUR and Rita HIEN Junior Business Developpers. Meryl Roudaut, our Project leader in metabolic tissues, and our Project director Elodie VANDENHAUTE will Read more…
Organoids are three-dimensional structures made of cells, which can be derived from stem cells to mimic the structure and function of real organs. They are useful tools for studying human development, disease modeling, drug screening, and personalized medicine. Recent advancements in organoid research have focused on improving their complexity and Read more…
Why is testing important? One million cases of colon cancer are diagnosed each year around the world. Colorectal cancer develops slowly. The tumor, called polyp, appears on the inner wall of the colon and rectum. The evolution of a polyp into cancer can last about ten years. The test can Read more…
We are pleased to participate in ELRIG event about Research an Innovation 2023 – Accelerating future drug discovery” in Cambridge on March 29 and 30th 2023. Veronique De Conto, our project leader in in vitro Pharmacology, is very happy to meet with you and to present you our disruptive technology Read more…
The beginning of 2023 is tremendous for HCS Pharma in terms of new oncology-related collaborative R&D projects, with three of them accepted and granted by ANR (Agence Nationale pour la Recherche) through the Plan France Relance, and by the Région Hauts-de-France through STIMuLE plan. It has been announced in a Read more…
The Brain Week is an international event organized simultaneously in about 100 countries and more than 120 cities in France. Its aim is to raise public awareness of the importance of brain research. It is an opportunity for many researchers to meet the public and share with them the advances Read more…
Poster presented during the SLAS event in San Diego on the 27th and 28th of February 2023. Title: BIOMIMESYS® Hydroscaffold, a ready-to-use organ-specific Extracellular Matrix for Relevant Phenotypic Screening Dr. Nathalie Maubon*, Dr. Véronique De Conto, Dr. Méryl Roudaut, Dr Alejandra Mogrovejo – Valdivia, Julien Leriche, Vaihere Cheung and Dr Read more…
We are glad starting a new Year! But nothing better than assessing what happened along the last one to glance back at the road traveled so far… and looking forward to what’s next!
BIOMIMESYS® is a patented 3D matrix reproducing the physicochemical properties of the extracellular matrix (ECM), different from classical hydrogels used for 3D cell culture. It is composed of native ECM components: Hyaluronic Acid (HA) combined with collagens, adhesion peptides… in the form of a unique hydroscaffold, i.e. exhibiting a dual Read more…
